Skip to main content
TipRanks
Go Ultimate75% OFF

Brainsway (BWAY) AI Stock Analysis

2 Followers
IL:BWAY

Brainsway

(TASE:BWAY)

Select Model
Rating:71Outperform
Price Target:ILA 3,648.00â–²(22.87% Upside)
Action:upgraded
Date:11/13/26

Brainsway's overall score of 71 is driven by its exceptional financial turnaround and a highly positive earnings call, which confirm strong commercial execution and a bright growth outlook. The company's robust, debt-free balance sheet and excellent cash flow generation provide a solid foundation. However, the score is significantly weighed down by weak technicals, with the stock in a clear downtrend across all major moving averages, and a high P/E ratio that leaves little room for error. The bearish market sentiment reflected in the technical indicators is the primary risk offsetting the company's strong fundamental performance.

Positive Factors
Installed Base and Recurring Revenue VisibilityA growing installed base and substantial remaining performance obligations support revenue visibility beyond individual equipment sales. Multiyear agreements, customer retention and enterprise relationships can deepen recurring revenue, improve utilization economics and make future growth more durable.
Negative Factors
Operating Expense Growth and Modest Operating MarginsHigher sales, research and administrative spending can absorb a meaningful portion of gross-profit gains, particularly while the operating margin remains modest for a high-gross-margin model. Continued investment may support growth, but it creates execution risk if revenue expansion does not outpace the cost base.

Brainsway (BWAY) vs. iShares MSCI Israel ETF (EIS)

0%25%50%75%100%125%IL:BWAY+22.53%EIS+9.40%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
ILS 1.22B
Dividend Yield
―
Average Volume (3M)
83.44K
Price to Earnings (P/E)
35.7
Beta (1Y)
0.65
Revenue Growth
15.22%
EPS Growth
33.08%
Country
Israel
Employees
129
Sector
Healthcare
Sector Strength
51
Industry
Medical - Specialties

Brainsway Business Overview & Revenue Model

Company Description

Established in Jerusalem, Israel, in 2003, BrainsWay Ltd. specializes globally in creating and distributing advanced, non-invasive neurostimulation therapies designed to address a wide array of mental health and neurological conditions. The company's...

How the Company Makes Money

BrainsWay primarily makes money by selling and/or leasing its Deep TMS systems to healthcare providers (such as psychiatry and neurology clinics) and generating ongoing revenue tied to the installed base of systems. Key revenue streams typically incl...

Brainsway Earnings Call Summary

Earnings Call Date:Nov 10, 2026(Q3-2026)|% Change Since:-18.72%|Next Earnings Date:Mar 17, 2027
Earnings Call SentimentPositive

The call was strongly positive, marked by 34% revenue growth, 44% growth in system shipments, expanding gross and operating margins, higher cash flow, increased reimbursement coverage, strong demand for SWIFT and OCD, and an outlook at the upper end of or potentially modestly above prior guidance. The company also reported preliminary clinical results, pending regulatory work, early-stage home-use commercialization and higher operating expenses, but these issues did not outweigh the reported financial and commercial progress.

Positive Updates

Strong Third-Quarter Revenue and System Shipments
BrainsWay shipped 130 Deep TMS systems during the third quarter, representing 44% year-over-year growth. Revenue increased 34% year-over-year to $18.1 million from $13.5 million, while revenue for the first nine months of 2026 increased 35% to $50.8 million.

Negative Updates

Higher Operating Expenses and Nonrecurring Charges
Third-quarter sales and marketing expenses increased to $5.5 million from $4.7 million, research and development expenses increased to $3.5 million from $2.4 million, and general and administrative expenses increased to $2.5 million from $1.8 million. Total operating expenses rose to $11.5 million from $8.9 million and included approximately $1 million of additional one-time expenses related to share-based compensation and other nonrecurring payments.

Company Guidance

For full year 2026, management expects results to be at the upper end of its previously issued guidance range, with the potential to modestly exceed those ranges; operating income is expected to be in the upper end of guidance. For 2027, management said there is no formal guidance, but expects operating expenses to increase between 15% to 20%, to continue and increase the margin, and cited book-to-bill of around 1.3 -- 1.4x. Management also expects international revenue growth of between 50% or even 100%, expects partnerships to open up between 50, sometimes even more locations in the next 3 years, and said the Alzheimer's feasibility study is expected to be completed by end of 2027, with a potential multicenter clinical trial costing between $3 million to $4 million over 2.5 or 3 years.

Brainsway Financial Statement Overview

Summary

Brainsway's financials depict a powerful turnaround. Revenue growth is accelerating (38% in 2025), profitability has swung from deep losses to a 14.6% net margin, and cash flow conversion is excellent at 96%. The balance sheet is a fortress with minimal debt (0.08 debt-to-equity) and rapidly growing equity. The only minor concern is slight TTM EBIT margin compression.

Income Statement

78Positive

Balance Sheet

85Very Positive

Cash Flow

82Very Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue69.81M56.53M41.02M31.79M27.18M29.66M
Gross Profit53.08M42.63M30.58M23.48M20.05M23.06M
EBITDA7.74M6.22M5.36M-2.56M-11.45M-4.67M
Net Income10.17M8.26M2.92M-4.20M-13.35M-6.46M
Balance Sheet
Total Assets127.17M112.94M94.32M62.97M64.48M75.73M
Cash, Cash Equivalents and Short-Term Investments64.07M69.13M69.34M45.98M47.85M57.35M
Total Debt6.95M6.82M5.62M471.00K488.00K754.00K
Total Liabilities40.56M34.67M32.00M21.39M19.08M18.41M
Stockholders Equity83.07M73.24M62.31M41.58M45.40M57.32M
Cash Flow
Free Cash Flow11.60M16.27M6.50M-1.10M-7.82M-1.35M
Operating Cash Flow12.06M18.02M10.30M1.28M-9.76M884.00K
Investing Cash Flow-50.81M-17.49M30.31M-37.41M42.17M-42.22M
Financing Cash Flow-3.09M-2.21M18.26M-1.03M-1.55M41.52M

Brainsway Technical Analysis

Technical Analysis SentimentNegative
Last Price2969.00

Price Trends

50DMA3735.22Negative
100DMA4167.56Negative
200DMA4191.72Negative

Market Momentum

MACD-177.17Positive
RSI28.00Positive
STOCH8.03Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:BWAY, the sentiment is Negative. The current price of 2969.00 is below the 20-day moving average (MA) of 3446.35, below the 50-day MA of 3735.22, and below the 200-day MA of 4191.72, indicating a bearish trend. The MACD of -177.17 indicates Positive momentum. The RSI at 28.00 is Positive, neither overbought nor oversold. The STOCH value of 8.03 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:BWAY.

Brainsway Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

IL:BWAY against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IL:SOFWIL:SOFW72OutperformILS 1.33B32.01――25.84%1717.73%
IL:BWAYIL:BWAY71OutperformILS 1.21B35.7213.07%―15.22%33.08%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%IL:BWAYIL:ILXIL:ALMDIL:EPITIL:SOFWIL:PLSMDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IL:BWAY and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IL:BWAYBrainsway 2969.00546.0022.53%
IL:ILXILEX Medical Ltd.4717.00-1878.73-28.48%
IL:ALMDAllmed Solutions Ltd.29.40-1.10-3.61%
IL:EPITEPITOMEE MEDICAL LTD246.60-493.90-66.70%
IL:SOFWSofwave Medical Ltd.3683.00783.0027.00%
IL:PLSMPulsenmore464.20-1925.86-80.58%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026